Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial  Anai E.S Durazzo, MD, Fábio S Machado, MD, Dimas T Ikeoka, MD, Cláudia De Bernoche, MD, Maristela C Monachini, MD, Pedro Puech-Leão, MD, Bruno Caramelli, MD  Journal of Vascular Surgery  Volume 39, Issue 5, Pages 967-975 (May 2004) DOI: 10.1016/j.jvs.2004.01.004

Fig 1 Flow diagram of trial phases. Journal of Vascular Surgery 2004 39, 967-975DOI: (10.1016/j.jvs.2004.01.004)

Fig 2 Event-free survival in the 6 months after vascular surgery, according to study group. Outcome measures included death from cardiac causes, nonfatal acute myocardial infarction, ischemic stroke, and unstable angina. Rate of event-free survival at 6 months (180 days) was 91.4% in the atorvastatin group and 73.5% in the placebo group (P = .018). Journal of Vascular Surgery 2004 39, 967-975DOI: (10.1016/j.jvs.2004.01.004)